178 related articles for article (PubMed ID: 8596630)
1. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.
Sumarsono SH; Wilson TJ; Tymms MJ; Venter DJ; Corrick CM; Kola R; Lahoud MH; Papas TS; Seth A; Kola I
Nature; 1996 Feb; 379(6565):534-7. PubMed ID: 8596630
[TBL] [Abstract][Full Text] [Related]
2. Ets transcription factors and targets in osteogenesis.
Raouf A; Seth A
Oncogene; 2000 Dec; 19(55):6455-63. PubMed ID: 11175361
[TBL] [Abstract][Full Text] [Related]
3. Ets2 transcription factor inhibits mineralization and affects target gene expression during osteoblast maturation.
Li V; Raouf A; Kitching R; Seth A
In Vivo; 2004; 18(5):517-24. PubMed ID: 15523888
[TBL] [Abstract][Full Text] [Related]
4. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
5. Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome.
Sanij E; Hatzistavrou T; Hertzog P; Kola I; Wolvetang EJ
Biochem Biophys Res Commun; 2001 Oct; 287(4):1003-8. PubMed ID: 11573964
[TBL] [Abstract][Full Text] [Related]
6. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
7. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.
Neznanov N; Man AK; Yamamoto H; Hauser CA; Cardiff RD; Oshima RG
Cancer Res; 1999 Sep; 59(17):4242-6. PubMed ID: 10485465
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis.
Wolvetang EJ; Bradfield OM; Hatzistavrou T; Crack PJ; Busciglio J; Kola I; Hertzog PJ
Neurobiol Dis; 2003 Dec; 14(3):349-56. PubMed ID: 14678752
[TBL] [Abstract][Full Text] [Related]
9. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome.
Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G
Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849
[TBL] [Abstract][Full Text] [Related]
10. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.
Wolvetang EW; Bradfield OM; Tymms M; Zavarsek S; Hatzistavrou T; Kola I; Hertzog PJ
Biochim Biophys Acta; 2003 Jul; 1628(2):105-10. PubMed ID: 12890557
[TBL] [Abstract][Full Text] [Related]
11. Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene.
Groner Y; Elroy-Stein O; Avraham KB; Yarom R; Schickler M; Knobler H; Rotman G
J Physiol (Paris); 1990; 84(1):53-77. PubMed ID: 1972759
[TBL] [Abstract][Full Text] [Related]
12. ERF: genomic organization, chromosomal localization and promoter analysis of the human and mouse genes.
Liu D; Pavlopoulos E; Modi W; Moschonas N; Mavrothalassitis G
Oncogene; 1997 Mar; 14(12):1445-51. PubMed ID: 9136988
[TBL] [Abstract][Full Text] [Related]
13. In vivo modulation of ETS genes induced by electromagnetic fields.
Mucci N; Ianni A; Ursini CL; Arzani D; Bhat NK; Navarra P; Romano-Spica V
In Vivo; 2001; 15(6):489-94. PubMed ID: 11887334
[TBL] [Abstract][Full Text] [Related]
14. Expression of the transcription factor ETS2 in brain of patients with Down syndrome--evidence against the overexpression-gene dosage hypothesis.
Greber-Platzer S; Schatzmann-Turhani D; Cairns N; Balcz B; Lubec G
J Neural Transm Suppl; 1999; 57():269-81. PubMed ID: 10666682
[TBL] [Abstract][Full Text] [Related]
15. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.
Wolvetang EJ; Wilson TJ; Sanij E; Busciglio J; Hatzistavrou T; Seth A; Hertzog PJ; Kola I
Hum Mol Genet; 2003 Feb; 12(3):247-55. PubMed ID: 12554679
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for Down syndrome.
Gjertson C; Sturm KS; Berger CN
Clin Immunol; 1999 Apr; 91(1):50-60. PubMed ID: 10219254
[TBL] [Abstract][Full Text] [Related]
17. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.
Sapi E; Flick MB; Rodov S; Kacinski BM
Cancer Res; 1998 Mar; 58(5):1027-33. PubMed ID: 9500466
[TBL] [Abstract][Full Text] [Related]
18. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
[TBL] [Abstract][Full Text] [Related]
19. Gene for porcine pregnancy-associated glycoprotein 2 (poPAG2): its structural organization and analysis of its promoter.
Szafranska B; Miura R; Ghosh D; Ezashi T; Xie S; Roberts RM; Green JA
Mol Reprod Dev; 2001 Oct; 60(2):137-46. PubMed ID: 11553911
[TBL] [Abstract][Full Text] [Related]
20. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer.
Tymms MJ; Ng AY; Thomas RS; Schutte BC; Zhou J; Eyre HJ; Sutherland GR; Seth A; Rosenberg M; Papas T; Debouck C; Kola I
Oncogene; 1997 Nov; 15(20):2449-62. PubMed ID: 9395241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
